Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Andrew Ustianowski; Joop E. Arends

doi:10.1007/s40121-015-0070-1

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Andrew Ustianowski^*, Joop E. Arends

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

13 Citations (Scopus)

Abstract

Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.

Original language	English
Pages (from-to)	145-157
Number of pages	13
Journal	Infectious Diseases and Therapy
Volume	4
Issue number	2
DOIs	https://doi.org/10.1007/s40121-015-0070-1
Publication status	Published - 19 Jun 2015

Keywords

Efficacy
HIV
Tenofovir
Toxicity

Access to Document

10.1007/s40121-015-0070-1

Cite this

@article{f47f606c1066408ab5542b66e28e79ca,

title = "Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use",

abstract = "Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.",

keywords = "Efficacy, HIV, Tenofovir, Toxicity",

author = "Andrew Ustianowski and Arends, {Joop E.}",

year = "2015",

month = jun,

day = "19",

doi = "10.1007/s40121-015-0070-1",

language = "English",

volume = "4",

pages = "145--157",

number = "2",

}

TY - JOUR

T1 - Tenofovir

T2 - What We Have Learnt After 7.5 Million Person-Years of Use

AU - Ustianowski, Andrew

AU - Arends, Joop E.

PY - 2015/6/19

Y1 - 2015/6/19

N2 - Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.

AB - Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.

KW - Efficacy

KW - HIV

KW - Tenofovir

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84977138177&partnerID=8YFLogxK

U2 - 10.1007/s40121-015-0070-1

DO - 10.1007/s40121-015-0070-1

M3 - Review article

AN - SCOPUS:84977138177

SN - 2193-8229

VL - 4

SP - 145

EP - 157

JO - Infectious Diseases and Therapy

JF - Infectious Diseases and Therapy

IS - 2

ER -

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this